Copy to clipboard 
ATEC reported 4Q25 orthopedic sales of $212.9 million, up 20.4% compared to the fourth quarter of 2024. For the full year, the company generated $764.2 million in orthopedic sales, up 25% compared to the prior year.
Highlights from 2025 include 22% surgical volume growth and 3% average revenue per case growth. ATEC’s focus on ecosystems dedicated to a specific pathology has built trust and confidence among surgeons, who are more likely to increase adoption and utilization across more of the company’s spine portfolio.
The Valence system will serve as a centerpiece to ATEC’s interoperative strategy, and is set for a controlled release throughout the year.
Additionally, EOS has increased the company’s standing among deformity surgeons, opening access to accounts where ATEC previously had no presence.
“We compel surgeons through clinical distinction, often beginning with lateral,” said ATEC CFO Todd Koning. “That initial adoption creates a halo effect across additional procedures driving predictable utilization growth over time. Each new surgeon relationship that we develop typically unlocks a multiyear utilization growth opportunity. If historical utilization trends persist, a significant portion of the case volume implied in our 2026 guide can be supported by existing surgeons alone before accounting for incremental new surgeon additions.”
ATEC expects $890 million in total sales for 2026, up 16.5% compared to the prior year.
Orthopedic Sales Data
Unless otherwise noted, all orthopedic sales data is provided in USD millions. We estimate orthopedic sales and growth rates on an as-reported basis.
Orthopedic Sales by Segment
| Segment | 4Q25 | 4Q24 | $ Chg | % Chg |
|---|---|---|---|---|
| Spine | $171.6 | $141.5 | $30.2 | 21.3% |
| Orthobiologics | $18.3 | $15.0 | $3.3 | 21.9% |
| Enabling Technology | $23.0 | $20.3 | $2.7 | 13.3% |
| Total | $212.9 | $176.8 | $36.1 | 20.4% |
| Segment | FY25 | FY24 | $ Chg | % Chg |
|---|---|---|---|---|
| Spine | $622.2 | $492.9 | $129.2 | 26.2% |
| Orthobiologics | $65.0 | $52.0 | $13.0 | 25.1% |
| Enabling Technology | $77.0 | $66.7 | $10.3 | 15.5% |
| Total | $764.2 | $611.6 | $152.6 | 25% |
Orthopedic Sales by Geography
| Region | 4Q25 | 4Q24 | $ Chg | % Chg |
|---|---|---|---|---|
| US | $197.6 | $163.2 | $34.4 | 21.1% |
| OUS | $15.3 | $13.6 | $1.7 | 12.6% |
| Total | $212.9 | $176.8 | $36.1 | 20.4% |
| Region | FY25 | FY24 | $ Chg | % Chg |
|---|---|---|---|---|
| US | $716.1 | $571.3 | $144.9 | 25.4% |
| OUS | $48.0 | $40.3 | $7.7 | 19.2% |
| Total | $764.2 | $611.6 | $152.6 | 25% |
Company Earnings
| Amt | % of Sales | |
|---|---|---|
| Sales | $212.9 | |
| Cost of Sales | $53.4 | 25.1% |
| Selling and Admin | $128.7 | 60.4% |
| R & D | $22.3 | 10.5% |
| Other | $30.2 | 14.2% |
| Net Earnings | ($21.7) | (10.2%) |
ATEC reported 4Q25 orthopedic sales of $212.9 million, up 20.4% compared to the fourth quarter of 2024. For the full year, the company generated $764.2 million in orthopedic sales, up 25% compared to the prior year.
Highlights from 2025 include 22% surgical volume growth and 3% average revenue per case growth. ATEC's focus on ecosystems...
ATEC reported 4Q25 orthopedic sales of $212.9 million, up 20.4% compared to the fourth quarter of 2024. For the full year, the company generated $764.2 million in orthopedic sales, up 25% compared to the prior year.
Highlights from 2025 include 22% surgical volume growth and 3% average revenue per case growth. ATEC’s focus on ecosystems dedicated to a specific pathology has built trust and confidence among surgeons, who are more likely to increase adoption and utilization across more of the company’s spine portfolio.
The Valence system will serve as a centerpiece to ATEC’s interoperative strategy, and is set for a controlled release throughout the year.
Additionally, EOS has increased the company’s standing among deformity surgeons, opening access to accounts where ATEC previously had no presence.
“We compel surgeons through clinical distinction, often beginning with lateral,” said ATEC CFO Todd Koning. “That initial adoption creates a halo effect across additional procedures driving predictable utilization growth over time. Each new surgeon relationship that we develop typically unlocks a multiyear utilization growth opportunity. If historical utilization trends persist, a significant portion of the case volume implied in our 2026 guide can be supported by existing surgeons alone before accounting for incremental new surgeon additions.”
ATEC expects $890 million in total sales for 2026, up 16.5% compared to the prior year.
Orthopedic Sales Data
Unless otherwise noted, all orthopedic sales data is provided in USD millions. We estimate orthopedic sales and growth rates on an as-reported basis.
Orthopedic Sales by Segment
| Segment | 4Q25 | 4Q24 | $ Chg | % Chg |
|---|---|---|---|---|
| Spine | $171.6 | $141.5 | $30.2 | 21.3% |
| Orthobiologics | $18.3 | $15.0 | $3.3 | 21.9% |
| Enabling Technology | $23.0 | $20.3 | $2.7 | 13.3% |
| Total | $212.9 | $176.8 | $36.1 | 20.4% |
| Segment | FY25 | FY24 | $ Chg | % Chg |
|---|---|---|---|---|
| Spine | $622.2 | $492.9 | $129.2 | 26.2% |
| Orthobiologics | $65.0 | $52.0 | $13.0 | 25.1% |
| Enabling Technology | $77.0 | $66.7 | $10.3 | 15.5% |
| Total | $764.2 | $611.6 | $152.6 | 25% |
Orthopedic Sales by Geography
| Region | 4Q25 | 4Q24 | $ Chg | % Chg |
|---|---|---|---|---|
| US | $197.6 | $163.2 | $34.4 | 21.1% |
| OUS | $15.3 | $13.6 | $1.7 | 12.6% |
| Total | $212.9 | $176.8 | $36.1 | 20.4% |
| Region | FY25 | FY24 | $ Chg | % Chg |
|---|---|---|---|---|
| US | $716.1 | $571.3 | $144.9 | 25.4% |
| OUS | $48.0 | $40.3 | $7.7 | 19.2% |
| Total | $764.2 | $611.6 | $152.6 | 25% |
Company Earnings
| Amt | % of Sales | |
|---|---|---|
| Sales | $212.9 | |
| Cost of Sales | $53.4 | 25.1% |
| Selling and Admin | $128.7 | 60.4% |
| R & D | $22.3 | 10.5% |
| Other | $30.2 | 14.2% |
| Net Earnings | ($21.7) | (10.2%) |
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
ME
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
